JCC:吞噬运动蛋白1可以通过Rac1通路保护小鼠免受DSS诱导的结肠损伤

2018-10-05 MedSci MedSci原创

粘膜愈合是克罗恩病治疗中最新的治疗目标,获得此治疗目标可能会使炎症性肠病[IBD]的患者获得更长的临床缓解时间。因此,研究人员希望研究吞噬和细胞运动蛋白1 [ELMO1]在体外和体内伤口愈合中与炎症性肠病发病机制之间关系。

背景及目的
粘膜愈合是克罗恩病治疗中最新的治疗目标,获得此治疗目标可能会使炎症性肠病[IBD]的患者获得更长的临床缓解时间。因此,研究人员希望研究吞噬和细胞运动蛋白1 [ELMO1]在体外和体内伤口愈合中与炎症性肠病发病机制之间关系。

方法
研究人员首先进行RNA转录组测序以检测IBD患者的炎症肠管与相应非发炎组织之间mRNA的表达谱的差异,然后进行Gene Expression Omnibus [GEO]数据收集和蛋白质印迹分析,接着他们测定了ELMO1过表达或敲低对细胞迁移和增殖的影响。使用Rac1抑制剂[NSC23766]和Rac1下拉测定法评估这些作用对Rac1的依赖性。最后建立葡聚糖硫酸钠[DSS]诱导的结肠炎模型以评估ELMO1在结肠粘膜愈合中的作用。

结果
与相应的非炎症组织相比,ELMO1在炎症组织中明显上调。ELMO1过表达以Rac1依赖性方式增加细胞迁移。GEO分析显示ELMO1过表达首先影响参与细胞骨架调节和伤口愈合的途径,这通过增强的F-肌动蛋白染色和过量表达ELMO1的细胞中延长的片状伪足的数量可以证明。在DSS诱导的结肠炎中,pSin-EF2-ELMO1-Pur的全身递送减弱了结肠炎症并促进了结肠损伤的恢复。最后研究人员发现ELMO1的保护作用依赖于Rac1活化。

结论
ELMO1蛋白需要通过激活Rac1通路才能对肠上皮迁移的产生影响,从而保护小鼠免受DSS诱导的结肠损伤。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1397637, encodeId=e514139e63776, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Oct 07 01:22:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348170, encodeId=ddfa3481e0b5, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Oct 06 09:26:12 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348089, encodeId=d2de348089ed, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Oct 05 23:59:12 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348014, encodeId=8ce1348014e7, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Oct 05 10:41:15 CST 2018, time=2018-10-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1397637, encodeId=e514139e63776, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Oct 07 01:22:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348170, encodeId=ddfa3481e0b5, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Oct 06 09:26:12 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348089, encodeId=d2de348089ed, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Oct 05 23:59:12 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348014, encodeId=8ce1348014e7, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Oct 05 10:41:15 CST 2018, time=2018-10-05, status=1, ipAttribution=)]
    2018-10-06 kafei

    学习了谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1397637, encodeId=e514139e63776, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Oct 07 01:22:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348170, encodeId=ddfa3481e0b5, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Oct 06 09:26:12 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348089, encodeId=d2de348089ed, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Oct 05 23:59:12 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348014, encodeId=8ce1348014e7, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Oct 05 10:41:15 CST 2018, time=2018-10-05, status=1, ipAttribution=)]
    2018-10-05 121832a9m88暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1397637, encodeId=e514139e63776, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sun Oct 07 01:22:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348170, encodeId=ddfa3481e0b5, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sat Oct 06 09:26:12 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348089, encodeId=d2de348089ed, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Fri Oct 05 23:59:12 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348014, encodeId=8ce1348014e7, content=谢谢分享,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Fri Oct 05 10:41:15 CST 2018, time=2018-10-05, status=1, ipAttribution=)]
    2018-10-05 liumin1987

    谢谢分享,学习了。

    0

相关资讯

IBD :Faecalibacterium prausnitzii菌通过制造丁酸盐改善结肠直肠结肠炎

炎症性肠病(IBD)相关的微生态失调的特征在于普鲁氏芽孢杆菌的丧失,而这种细菌的上清液发挥着抗炎的作用。然而,F. prausnitzii菌上清液中的抗炎物质和改善IBD结肠炎的机制尚未得到充分研究。本项研究就此开展了相关的研究。

JCC:肠系膜淋巴结微生物组成可以区分克罗恩病和溃疡性结肠炎

肠系膜淋巴结是易位细菌介导炎症发生并引起免疫反应的关键部位。因此,了解炎症性肠病中肠系膜淋巴结的微生物组成很重要。本研究旨在研究克罗恩病和溃疡性结肠炎患者的肠系膜淋巴结微生物群之间的差异。

JCC: 戈利木单抗对中度至重度活动性溃疡性结肠炎患者能起到长期缓解

戈利木单抗已经在治疗溃疡性结肠炎中得到广泛应用,因此,本项研究旨在评估中度至重度活动性溃疡性结肠炎患者的皮下注射戈利木单抗维持的安全性和有效性的情况。

JCC:抗肿瘤坏死因子α在治疗炎症性肠病患者并不增加淋巴瘤发生的风险

目前有些研究报道了抗肿瘤坏死因子α试剂与炎性肠病患者中淋巴瘤发生风险之间的关联。但是,这些研究的结果并不一致。因此,有研究人员进行了一项meta分析进行了相关验证。

JCC : 抗肿瘤坏死因子在影响炎性肠病患者潜在发生结核感染的前瞻性研究

生物疗法彻底改变了免疫介导疾病的治疗方法,特别是炎症性肠病[IBD]和风湿病。然而,生物治疗与潜伏性结核再激活的风险增加有关。生物治疗期间定期监测潜伏性结核感染[LTBI]的重要性目前还没有得到应有的重视。

JCC: 尤特科单抗(Ustekinumab)对中度至重度克罗恩病患者健康相关生活质量的影响

尤特科单抗(ustekinumab)作为一种治疗克罗恩病的新药, 目前对于它的研究还比较匮乏,本项研究旨在研究其对克罗恩病患者健康相关生活质量[HRQOL]的影响。